Eli Lilly to put Loxo executives in charge of new cancer research unit
Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. “This will be a significant cost saving for many of our urological patients with erectile dysfunction, including those experiencing side effects from …
Eli Lilly to put Loxo executives in charge of new cancer research unit Read More »